RESPIRATORY VIRUS INFECTION DRUGS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-134375 | Health Care
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Respiratory Virus Infection Drugs Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL RESPIRATORY VIRUS INFECTION DRUGS MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL RESPIRATORY VIRUS INFECTION DRUGS MARKET
7.1 GLOBAL RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA RESPIRATORY VIRUS INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 AstraZeneca plc (United Kingdom)
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 AbbVie Inc. (United States)
16.3 Ablynx NV (Belgium)
16.4 ADMA Biologics (United States)
16.5 Alnylam Pharmaceuticals, Inc. (United States)
16.6 Ark Biosciences (China)
16.7 ImmunoVaccine Technologies (Canada)
16.8 Aviragen Therapeutics (United States)
16.9 Boehringer Ingelheim (Germany)
16.10 Bavarian Nordic (Denmark)
16.11 Gilead Sciences, Inc. (United States)
16.12 Johnson & Johnson (United States)
16.13 Kyowa Hakko Kirin Co., Ltd. (Japan)
16.14 Mymetics Corporation (Switzerland)
16.15 GlaxoSmithKline plc. (United Kingdom)
16.16 Teva Pharmaceutical (Israel)
16.17 Vaxart, Inc. (United States)
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypePenicillin VK
Amoxicillin
Penicillin G benzathine
Cefadroxil
Erythromycin
Amoxicillin and clavulanate
Others
By Disease Type
COVID-19
URTI
Influenza
Bronchiolitis
Pneumonia
Measles
Others
By End-users
Hospitals
Clinics
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By Dug Class
Nucleoside Analogues
Neuraminidase Inhibitors
Ion Channel Blockers
Fusion Protein Inhibitors
Companies
AstraZeneca plc (United Kingdom)
AbbVie Inc. (United States)
Ablynx NV (Belgium)
ADMA Biologics (United States)
Alnylam Pharmaceuticals, Inc. (United States)
Ark Biosciences (China)
ImmunoVaccine Technologies (Canada)
Aviragen Therapeutics (United States)
Boehringer Ingelheim (Germany)
Bavarian Nordic (Denmark)
Gilead Sciences, Inc. (United States)
Johnson & Johnson (United States)
Kyowa Hakko Kirin Co., Ltd. (Japan)
Mymetics Corporation (Switzerland)
GlaxoSmithKline plc. (United Kingdom)
Teva Pharmaceutical (Israel)
Vaxart, Inc. (United States)
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.